296 related articles for article (PubMed ID: 25169560)
1. Dyslipidemia and cardiovascular risk in human immunodeficiency virus infection.
Kelesidis T; Currier JS
Endocrinol Metab Clin North Am; 2014 Sep; 43(3):665-84. PubMed ID: 25169560
[TBL] [Abstract][Full Text] [Related]
2. Systemic and cell-specific mechanisms of vasculopathy induced by human immunodeficiency virus and highly active antiretroviral therapy.
Haser GC; Sumpio B
J Vasc Surg; 2017 Mar; 65(3):849-859. PubMed ID: 26994951
[TBL] [Abstract][Full Text] [Related]
3. Lipid metabolism in treated HIV Infection.
Dubé MP; Cadden JJ
Best Pract Res Clin Endocrinol Metab; 2011 Jun; 25(3):429-42. PubMed ID: 21663837
[TBL] [Abstract][Full Text] [Related]
4. HIV and its relationship to insulin resistance and lipid abnormalities.
Non LR; Escota GV; Powderly WG
Transl Res; 2017 May; 183():41-56. PubMed ID: 28068521
[TBL] [Abstract][Full Text] [Related]
5. Management of dyslipidemia in patients with human immunodeficiency virus.
Shalit P
Rev Cardiovasc Med; 2014; 15 Suppl 1():S38-46. PubMed ID: 24987862
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular disease in HIV infection.
Sánchez-Torres RJ; García-Palmieri MR
P R Health Sci J; 2006 Sep; 25(3):249-54. PubMed ID: 17203795
[TBL] [Abstract][Full Text] [Related]
7. The roles of genetic polymorphisms and human immunodeficiency virus infection in lipid metabolism.
de Almeida ER; Reiche EM; Kallaur AP; Flauzino T; Watanabe MA
Biomed Res Int; 2013; 2013():836790. PubMed ID: 24319689
[TBL] [Abstract][Full Text] [Related]
8. Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virus.
Beltrán LM; Rubio-Navarro A; Amaro-Villalobos JM; Egido J; García-Puig J; Moreno JA
Vasc Health Risk Manag; 2015; 11():35-48. PubMed ID: 25609975
[TBL] [Abstract][Full Text] [Related]
9. Dyslipidemia and lipid management in HIV-infected patients.
Lo J
Curr Opin Endocrinol Diabetes Obes; 2011 Apr; 18(2):144-7. PubMed ID: 21297466
[TBL] [Abstract][Full Text] [Related]
10. [Lipid alterations and cardiovascular risk associated with antiretroviral therapy].
Masiá-Canuto M; Bernal-Morell E; Gutiérrez-Rodero F
Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):637-48. PubMed ID: 17194390
[TBL] [Abstract][Full Text] [Related]
11. Obesity and dyslipidemia in behaviorally HIV-infected young women: Adolescent Trials Network study 021.
Mulligan K; Harris DR; Monte D; Stoszek S; Emmanuel P; Hardin DS; Kapogiannis BG; Worrell C; Meyer WA; Sleasman J; Wilson CM; Aldrovandi GM;
Clin Infect Dis; 2010 Jan; 50(1):106-14. PubMed ID: 19947855
[TBL] [Abstract][Full Text] [Related]
12. The Evolving Landscape of ASCVD Risk Among Patients With HIV.
Malvestutto C
J Fam Pract; 2022 Jul; 71(6 Suppl):S58-S62. PubMed ID: 35960946
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of Dyslipidemia Among Antiretroviral-Naive HIV-Infected Individuals in China.
Shen Y; Wang J; Wang Z; Qi T; Song W; Tang Y; Liu L; Zhang R; Lu H
Medicine (Baltimore); 2015 Dec; 94(48):e2201. PubMed ID: 26632908
[TBL] [Abstract][Full Text] [Related]
14. Dyslipidemia and its Treatment in HIV Infection.
Grunfeld C
Top HIV Med; 2010; 18(3):112-8. PubMed ID: 20921577
[TBL] [Abstract][Full Text] [Related]
15. Dyslipidemia in Human Immunodeficiency Virus Disease: JACC Review Topic of the Week.
Kalra DK; Vorla M; Michos ED; Agarwala A; Virani S; Duell PB; Raal FJ
J Am Coll Cardiol; 2023 Jul; 82(2):171-181. PubMed ID: 37407116
[TBL] [Abstract][Full Text] [Related]
16. HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients.
Kotler DP
J Acquir Immune Defic Syndr; 2008 Sep; 49 Suppl 2():S79-85. PubMed ID: 18725816
[TBL] [Abstract][Full Text] [Related]
17. Lipoatrophy among patients on antiretroviral therapy in Lagos, Nigeria: Prevalence, pattern and association with cardiovascular risk factors.
Iwuala SO; Lesi OA; Olamoyegun MA; Sabir AA; Fasanmade OA
Niger J Clin Pract; 2015; 18(5):626-32. PubMed ID: 26096241
[TBL] [Abstract][Full Text] [Related]
18. Update on metabolic issues in HIV patients.
Calvo M; Martinez E
Curr Opin HIV AIDS; 2014 Jul; 9(4):332-9. PubMed ID: 24824886
[TBL] [Abstract][Full Text] [Related]
19. Lipidome Abnormalities and Cardiovascular Disease Risk in HIV Infection.
Bowman E; Funderburg NT
Curr HIV/AIDS Rep; 2019 Jun; 16(3):214-223. PubMed ID: 30993515
[TBL] [Abstract][Full Text] [Related]
20. [CME: Dyslipidemia and Cardiovascular Risk in HIV Infected Patients].
Tschumi F; Brugger SD; Braun DL
Praxis (Bern 1994); 2019; 108(7):451-458. PubMed ID: 31136273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
